Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Glen Titmarsh is active.

Publication


Featured researches published by Glen Titmarsh.


American Journal of Hematology | 2014

How common are myeloproliferative neoplasms? A systematic review and meta-analysis.

Glen Titmarsh; Andrew S Duncombe; Mary Frances McMullin; Michael O'Rorke; Ruben A. Mesa; Frank de Vocht; Sarah Horan; Lin Fritschi; Mike Clarke; Lesley A. Anderson

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including polycythemia vera (PV), essential thrombocythemia (ET), and primary(idiopathic) myelofibrosis (PMF). In this systematic review, we provide a comprehensive report on the incidence and prevalence of MPNs across the globe. Electronic databases (PubMed, EMBASE, MEDLINE, and Web of Science) were searched from their inception to August 2012 for articles reporting MPN incidence or prevalence rates. A random effects meta‐analysis was undertaken to produce combined incidence rates for PV, ET, and PMF. Both heterogeneity and small study bias were assessed. Thirty‐four studies were included. Reported annual incidence rates ranged from 0.01 to 2.61, 0.21 to 2.27, and 0.22 to 0.99 per 100,000 for PV, ET, and PMF, respectively. The combined annual incidence rates for PV, ET, and PMF were 0.84, 1.03, and 0.47 per 100,000. There was high heterogeneity across disease entities (I2 97.1–99.8%) and evidence of publication bias for ET and PMF (Egger test, P = 0.007 and P ≤ 0.001, respectively).The pooled incidence reflects the rarity of MPNs. The calculated pooled incidence rates do not reflect MPN incidence across the globe due to the high unexplained heterogeneity. Improved, widespread registration of MPNs would provide better information for global comparison of the incidence and prevalence of MPNs. Am. J. Hematol. 89:581–587, 2014.


British Journal of Cancer | 2014

Common infection-related conditions and risk of lymphoid malignancies in older individuals

Lesley A. Anderson; A A Atman; Charlene McShane; Glen Titmarsh; Eric A. Engels; J Koshiol

Background:Chronic antigenic stimulation may initiate non-Hodgkin (NHL) and Hodgkin lymphoma (HL) development. Antecedent, infection-related conditions have been associated, but evidence by lymphoproliferative subtype is limited.Methods:From the US SEER-Medicare database, 44 191 NHL, 1832 HL and 200 000 population-based controls, frequency-matched to all SEER cancer cases, were selected. Logistic regression models, adjusted for potential confounders, compared infection-related conditions in controls with HL and NHL patients and by the NHL subtypes diffuse large B-cell, T-cell, follicular and marginal zone lymphoma (MZL). Stratification by race was undertaken.Results:Respiratory tract infections were broadly associated with NHL, particularly MZL. Skin infections were associated with a 15–28% increased risk of NHL and with most NHL subtypes, particularly cellulitis with T-cell lymphoma (OR 1.36, 95%CI 1.24–1.49). Only herpes zoster remained associated with HL following Bonferroni correction (OR 1.55, 95% CI 1.28–1.87). Gastrointestinal and urinary tract infections were not strongly associated with NHL or HL. In stratified analyses by race, sinusitis, pharyngitis, bronchitis and cellulitis showed stronger associations with total NHL in blacks than whites (P<0.001).Conclusions:Infections may contribute to the aetiologic pathway and/or be markers of underlying immune modulation. Precise elucidation of these mechanisms may provide important clues for understanding how immune disturbance contributes to lymphoma.


Cancer Epidemiology | 2014

Community-acquired infections and their association with myeloid malignancies

Glen Titmarsh; Mary Frances McMullin; Charlene McShane; Mike Clarke; Eric A. Engels; Lesley A. Anderson

INTRODUCTION Antigenic stimulation is a proposed aetiologic mechanism for many haematological malignancies. Limited evidence suggests that community-acquired infections may increase the risk of acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS). However, associations with other myeloid malignancies including chronic myeloid leukaemia (CML) and myeloproliferative neoplasms (MPNs) are unknown. MATERIALS AND METHODS Using the Surveillance, Epidemiology and End Result (SEER)-Medicare database, fourteen community-acquired infections were compared between myeloid malignancy patients [AML (n=8489), CML (n=3626) diagnosed 1992-2005; MDS (n=3072) and MPNs (n=2001) diagnosed 2001-2005; and controls (200,000 for AML/CML and 97,681 for MDS/MPN]. Odds ratios (ORs) and 95% confidence intervals were adjusted for gender, age and year of selection excluding infections diagnosed in the 13-month period prior to selection to reduce reverse causality. RESULTS Risk of AML and MDS respectively, were significantly associated with respiratory tract infections, bronchitis (ORs 1.20 [95% CI: 1.14-1.26], 1.25 [95% CI: 1.16-1.36]), influenza (ORs 1.16 [95% CI: 1.07-1.25], 1.29 [95% CI: 1.16-1.44]), pharyngitis (ORs 1.13 [95% CI: 1.06-1.21], 1.22 [95% CI: 1.11-1.35]), pneumonia (ORs 1.28 [95% CI: 1.21-1.36], 1.52 [95% CI: 1.40-1.66]), sinusitis (ORs 1.23 [95% CI: 1.16-1.30], 1.25 [95% CI: 1.15-1.36]) as was cystitis (ORs 1.13 [95% CI: 1.07-1.18], 1.26 [95% CI: 1.17-1.36]). Cellulitis (OR 1.51 [95% CI: 1.39-1.64]), herpes zoster (OR 1.31 [95% CI: 1.14-1.50]) and gastroenteritis (OR 1.38 [95% CI: 1.17-1.64]) were more common in MDS patients than controls. For CML, associations were limited to bronchitis (OR 1.21 [95% CI: 1.12-1.31]), pneumonia (OR 1.49 [95% CI: 1.37-1.62]), sinusitis (OR 1.19 [95% CI: 1.09-1.29]) and cellulitis (OR 1.43 [95% CI: 1.32-1.55]) following Bonferroni correction. Only cellulitis (OR 1.34 [95% CI: 1.21-1.49]) remained significant in MPN patients. Many infections remained elevated when more than 6 years of preceding claims data were excluded. DISCUSSION Common community-acquired infections may be important in the malignant transformation of the myeloid lineage. Differences in the aetiology of classic MPNs and other myeloid malignancies require further exploration.


American Journal of Hematology | 2015

How common are myeloproliferative neoplasms? A systematic review and meta-analysis [Am. J. Hematol. 89: 581-587, 2014. DOI: 10.1002/ajh.23690]

Glen Titmarsh; Andrew S Duncombe; Mary Frances McMullin; Michael O'Rorke; Ruben A. Mesa; Frank de Vocht; Sarah Horan; Lin Fritschi; Mike Clarke; Lesley A. Anderson

It has come to the author’s attention that an erratum needs to be published for the above study. Pooled incidence estimates were erroneously generated using fixed effects models (which is the default analysis of the statistical software) as opposed to random effects models as described in the methods section of the published manuscript. As we have accumulated data from a series of studies that have been performed independently in different populations and countries, it would be unlikely that all the studies would have reported a common incidence for the myeloproliferative conditions investigated. In such circumstances, with expected heterogeneity between studies, incidence estimation from a random effects metaanalysis is the best approach to analysis.


Hematological Oncology | 2016

Minor allele frequency of myeloproliferative neoplasm mutations in the Irish blood donor population

Glen Titmarsh; Gareth J. McKay; Mark Lawler; Lesley A. Anderson; Mary Frances McMullin

Myeloproliferative neoplasms (MPNs) are rare diseases that include classic entities; polycythaemia vera, essential thrombocythaemia and primary myelofibrosis. In this short report, minor allele frequencies of common MPN mutations are compared between the Irish blood donor population and other populations of European descent using data from the Haplotype Map project. The Affymetrix array 6.0 platform was utilised identifying nine single nucleotide polymorphisms (SNPs) and six proxy SNPs. The variability of allele frequencies for MPN mutations could account for the different incidence rates seen between populations of European ancestry, giving a better understanding of the genetic predisposition to MPNs. Copyright


European School of Hematology International Conference on Myeloproliferative Neoplasms. | 2014

Allele Frequency of Myeloproliferative Neoplasm Mutations in the Irish Blood Donor Population

Glen Titmarsh; Gareth J. McKay; Mark Lawler; Lesley A. Anderson; Mary Frances McMullin


European School of Hematology International Conference on Myeloproliferative Neoplasms. | 2014

How common are the myeloproliferative neoplasms: a systematic review and meta-analysis

Glen Titmarsh; Mary Frances McMullin; Andrew S Duncombe; Sarah Horan; Michael O'Rorke; Mike Clarke; Lesley A. Anderson


European School of Hematology International Conference on Myeloproliferative Neoplasms. | 2014

The MOSAICC Study - Methodology

Glen Titmarsh; Lesley A. Anderson; Mary Frances McMullin; Mike Clarke; Andrew S Duncombe; F. de Vocht; Lin Fritschi; Ruben A. Mesa; M. Purdue; A. Frank


Infection and Immunity Translational Research Group meeting | 2013

Community-acquired infections and their association with myeloid malignancies.

Glen Titmarsh; Mary Frances McMullin; Charlene McShane; Eric A. Engels; Lesley A. Anderson


Haematology Association of Ireland Conference | 2013

How common are myeloproliferative neoplasms? A systematic review and meta-analysis

Glen Titmarsh; Mary Frances McMullin; Andrew S Duncombe; Sarah Horan; Michael O'Rorke; Mike Clarke; Lesley A. Anderson

Collaboration


Dive into the Glen Titmarsh's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mike Clarke

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Andrew S Duncombe

University Hospital Southampton NHS Foundation Trust

View shared research outputs
Top Co-Authors

Avatar

Charlene McShane

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Michael O'Rorke

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar

Eric A. Engels

National Institutes of Health

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge